Therefore, the activation of the PI3K/AKT pathway in LBC may result in intrinsic resistance to palbociclib after development of refractory disease to prior ET. The gene discussed is AKT1; the disease is CDH1-related diffuse gastric and lobular breast cancer syndrome.